Antipodes Emerging Markets (Managed Fund)
The Fund typically invests in a select number of attractively valued companies exposed to emerging markets or listed on emerging market stock exchanges (usually a minimum 30 long holdings).
The aim of the Fund is to achieve absolute returns in excess of the Benchmark over the investment cycle (typically 3-5 years)
The benchmark is the MSCI Emerging Markets Index.
The suggested minimum investment period is 5 years.
The Fund's risk profile is High. The Fund is willing to take high risk in search of greater returns, and investors are comfortable with volatility and with the high risk of negative returns, with the potential to produce higher returns over the long term. Investors aim to invest over a longer period.
The Fund invests in companies that are exposed to emerging markets or listed on emerging market stock exchanges.
Portfolio allocation
|
Asset Class |
Typical Allocation Range1 |
|
Global equities2 |
75% – 100% |
|
Cash |
0% - 25% |
1The above ranges are indicative only. The Fund will be rebalanced within a reasonable period of time should the exposure move outside of the above ranges.
2 The Fund may also use derivatives to manage equity and currency exposures.
Investment guidelines
- The Fund has a maximum single stock limit of 10% of the Fund’s NAV.
- The top 10 positions will typically account for 25% to 35% of the portfolio and the top 30 positions 60% to 80%.
- The Fund is also permitted to also hold fixed income and debt securities, bullion, and other physical commodities.
Antipodes believes that equity investment returns are primarily a function of:
-
economic performance of the business and the resilience of this performance; and
- price paid or starting valuation at the time of purchase.
Antipodes seeks to mitigate the risk of permanent loss of capital and/or unforeseen downside volatility by:
- ensuring the price paid for a stock represents a discount to intrinsic value, and
- developing a deep understanding of each stock within the context of the broader portfolio.
Click here to view our latest Performance.
All website content in respect of the Antipodes Emerging Markets (Managed Fund) (ARSN 096 451 393) (the Fund) is issued by Pinnacle Fund Services Limited ABN 29 082 494 371 AFSL 238 371 (“PFSL”) as responsible entity of the Fund and is prepared by Antipodes Partners Limited (ABN 29 602 042 035) (AFSL 481580) (“Antipodes”) as the investment manager of the Trust. PFSL is not licensed to provide financial product advice.
The information provided in this website is of a general nature only and has been prepared without taking into account your objectives, financial situation or needs. Before making an investment decision in respect of the Fund, you should consider the current product disclosure statement (PDS) and Target Market Determination (‘TMD’) of the Fund and the Fund’s other periodic and continuous disclosure announcements lodged with the ASX, which are available at www.asx.com.au, and assess whether the Fund is appropriate given your objectives, financial situation or needs. If you require advice that takes into account your personal circumstances, you should consult a licensed or authorised financial adviser.
Neither PFSL nor Antipodes guarantees repayment of capital or any particular rate of return from the Fund. Neither PFSL nor Antipodes gives any representation or warranty as to the currency, reliability, completeness or accuracy of the information contained in this website. All opinions and estimates included in this website constitute judgments of Antipodes as at the date of website creation and are subject to change without notice. Past performance is not a reliable indicator of future performance.
The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) (“Zenith”) rating (assigned Antipodes Emerging Markets (Managed Fund) – November 2022) referred to on this website is limited to “General Advice” (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith’s methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at Fund Research Regulatory Guidelines.
The Lonsec Ratings (assigned as follows: Antipodes Emerging Markets (Managed Fund) – May 2022) presented in this document are published by Lonsec Research presented in this document are published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421445. The Ratings are limited to “General Advice” (as defined in the Corporations Act 2001 (Cth)) and based solely on consideration of the investment merits of the financial products. Past performance information is for illustrative purposes only and is not indicative of future performance. They are not a recommendation to purchase, sell or hold Antipodes products, and you should seek independent financial advice before investing in these products. The Ratings are subject to change without notice and Lonsec assumes no obligation to update the relevant documents following publication. Lonsec receives a fee from the Fund Manager for researching the products using comprehensive and objective criteria. For further information regarding Lonsec’s Ratings methodology, please refer to our website at https://www.beyond.lonsec.com.au/intelligence/lonsec-ratings.
Evergreen Research Pty Ltd trading as ERIG Index ABN 17 647 506 590 is Authorised Representative 001289533 of Evergreen Fund Managers Pty Ltd ABN 75 602 703 202AFSL 486275. The material is for the information purposes of non-retail clients only.It is not, and is not to be construed as, advice or a recommendation to acquire, hold or dispose of financial products or to use financial services. The ERIG Index measures only the Responsible Investment capabilities of funds. It does not assess the performance or other features of the funds.
Antipodes is a global asset manager offering a pragmatic value approach across long only and long short strategies. Antipodes aspires to grow client wealth over the long-term by generating absolute returns in excess of the Benchmark at below market levels of risk.
Antipodes seeks to take advantage of the market’s tendency for irrational extrapolation, identify investments that offer a high margin of safety and build high conviction portfolios with a capital preservation focus. Antipodes is majority owned by its seasoned investment team and its performance culture is underpinned by sensible incentives, a focused offering and the outsourcing of non-investment functions to maximise focus on investing.
The Antipodes investment team is led by Jacob Mitchell, formerly Deputy Chief Investment Officer (CIO) of Platinum Asset Management. As CIO, Jacob is responsible for the implementation of the firm and Fund’s investment strategy.
Jacob and the Antipodes investment team spend as much time as required to accomplish the investment objectives of the Fund. Antipodes is majority-owned by its seasoned investment team and its performance culture is underpinned by sensible incentives, a focused offering and the outsourcing of non-investment functions to maximise focus on investing.
We believe in three principles of team empowerment – liberation, motivation and dedication.
The talented and experienced analysts and managers who join us are liberated from some of the constraints that have held them back at other firms.
Our approach gives them greater scope to explore and discover investment opportunities, and exposes them to a broad diversity of thought, analysis and style. Antipodes is majority owned by the members of our investment team.
They’re motivated by clarity of leadership and a remuneration model that both rewards their success and ensures that they remain in close alignment with the interests of our clients.
Their dedication comes not only from personal commitment, but from their sole focus on investing. If you study their biographies below, you’ll notice that we’ve drawn our team from a wide variety of abilities and interests. This is a core element of our strategy. As the name Antipodes suggests, we encourage the creative abrasion of contrary points of view that stimulates fresh and clear insights.
The construction of our team is designed to encourage this process of intellectual synergy. It adds breadth to our landscape of opportunity and a more profound understanding of the investments we make.
John is portfolio manager of the Emerging Markets domestic team, with coverage of consumer, domestic services, financials, technology, media and telecommunications
Prior to joining Antipodes in 2018, John was a sell-side Analyst with Morgan Stanley for four years focusing on emerging Australian companies in the retail, aged care and auto industries. Before this, John held Research Analyst roles with Bligh Capital Securities and Colonial First State.
John holds a Bachelor of Commerce (Actuarial Studies) and a Bachelor of Science (Mathematics and Statistics) from the University of New South Wales and is a CFA charter holder. John is fluent in Greek.
Jacob is the Founder and Chief Investment Officer of Antipodes.
Jacob was formerly Deputy Chief Investment Officer of Platinum Asset Management and a Portfolio Manager of the flagship Platinum International Fund. He resigned from Platinum effective December 2014 after more than 14 years at the firm during which he also served as Portfolio Manager for the Platinum Unhedged Fund (January 2007 to May 2014) and the Platinum Japan Fund (January 2008 to November 2014).
Prior to joining Platinum, Jacob was Head of Technology and Emerging Industrials Research at UBS Warburg Australia.
He commenced his investment career in 1994 at high conviction, value-based Australian equities manager, Tyndall Australia.
Qualifications: B. Com (University of Western Sydney)
Andrew has over 20 years experience in financial services across Australia, Hong Kong and Europe. His core focus has been on business management, product development, marketing and distribution.
Prior to joining Antipodes Andrew was a senior executive at Pinnacle Investment Management Limited which he joined in 2009. At Pinnacle he worked with investment professionals across a range of asset classes to establish, manage and grow their businesses. Before joining Pinnacle, Andrew worked at Macquarie Bank for over 5 years, based in both Sydney and Hong Kong.
Earlier in his career Andrew worked in a variety of financial marketing roles with Deutsche Bank in Australia, and with UBS in Zurich and London.
Qualifications: B. Com (University of New South Wales)
Click here to view our current Monthly Update.
Click here to view our current Quarterly Update.
If you have joined Investment Markets (which is free) and verified your email address, you can send an email directly to us either by: -
- Selecting “Enquire” when viewing the card relating to the listing; OR
- By completing the enquiry form on the lefthand side when viewing the detail of a listing
We will respond using your preferred communication method (i.e., email or phone).
Statutory Statement
The issuer of this product is identified at the top of this page. The PDS and target market determination for the product are available in the Documents section of this listing. Prospective investors should consider the PDS before deciding to acquire the product. This product listing was vetted by and approved by the product issuer identified above before publishing. Investment Markets (Aust) Pty Ltd AFSL 527875 (IM) is not the issuer of the product.
General Disclaimer
IMPORTANT STATEMENT ABOUT YOUR USE OF THIS SITE
Information on this site is intended for Australian users only.
This site is operated by Investment Markets (Aust) Pty Ltd. (ACN 634 057 248) (IMA, we, us and our), the holder of Australian Financial Services Licence (AFSL) no. 527875. The content is provided solely for information purposes, is not a recommendation or an offer to buy or sell a security, and is not warranted to be correct, complete or accurate. To the extent permitted by law, neither IMA, its affiliates, nor the content providers (such as the issuers of securities who appear on the site) are responsible for any investment decisions, damages or losses resulting from, or related to, the content, data and analyses or their use. The investment products on this site and any statements made about them by their issuers are not vetted, verified or researched by IMA. The presence of an investment product on this site should not be interpreted as an implied endorsement of it by IMA. Certain content provided may constitute a summary or extract of another document such as a Product Disclosure Statement. To the extent any content is general advice, it has been prepared by IMA. Any general advice has been provided without reference to your investment objectives, financial situations or needs. For more information refer to our Financial Services Guide. To obtain advice tailored to your situation, contact a financial advisor. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (or other offer document) before making any decision to invest. Past performance does not necessarily indicate an investment product’s future performance. The content is current as at date of initial publication and may not be current as at your date of viewing. For a more complete understanding of all the terms and conditions of your use of this site click here.